TLDR
- Humana delivered Q1 adjusted EPS of $10.31, surpassing analyst expectations of $10.19–$10.20
- Shares tumbled as much as 7.4% in premarket trading following the earnings release
- Company maintained full-year adjusted EPS guidance at $9 while reducing reported profit forecast to $8.36 from $8.89
- Declining Medicare Advantage Star Ratings for 2026 are impacting bonus payments and overall profitability
- Leadership highlighted widening disconnect between healthcare expenses and federal reimbursement rates
Humana delivered better-than-expected first-quarter results on Wednesday, yet the market responded with a sharp selloff. Shares plunged as much as 7.4% during premarket hours after the healthcare giant declined to raise its annual earnings projection while competitors moved theirs higher.
The company reported adjusted earnings of $10.31 per share, exceeding Wall Street’s consensus range of approximately $10.19–$10.20. Total revenue climbed to $39.65 billion from $32.11 billion in the prior-year period, also surpassing analyst forecasts of $39.37 billion.
Despite these solid numbers, investor sentiment soured quickly.
According to Morningstar analyst Julie Utterback, market participants likely anticipated that Humana would elevate its forward-looking projections following such a robust quarterly performance. Instead, the company stood pat.
Management reaffirmed its full-year adjusted earnings guidance of at least $9 per share. However, on a GAAP basis, the outlook was actually revised downward — now targeting at least $8.36 per share compared to the prior estimate of at least $8.89.
The downward adjustment stems from costs associated with a comprehensive transformation initiative, encompassing employee severance packages, asset write-downs, and external consulting fees.
Medicare Star Ratings Weigh on Earnings
Central to Humana’s current challenges are its diminished Medicare Advantage Star Ratings for the 2026 performance period. These quality metrics, ranging from one to five stars, directly influence bonus compensation from federal authorities. Reduced ratings translate to smaller bonus allocations.
The insurer has been signaling this obstacle for several quarters. First-quarter net income registered at $9.83 per share, declining from $10.30 in the same period last year — a clear consequence of this ongoing pressure.
CEO Jim Rechtin indicated that medical utilization patterns and associated costs aligned with internal projections. However, he emphasized that the disparity between the company’s healthcare expenditures and government reimbursements has expanded year-over-year.
“Every year we’re going to step back and look at our whole portfolio,” Rechtin said.
Benefit Ratio Comes in Better Than Expected
Amid the headwinds, one metric stood out positively: Humana’s insurance division’s benefit ratio — representing the portion of premium revenue allocated to medical expenses — registered 89.4% for the quarter. This figure outperformed the company’s internal forecast of just under 90% and beat analyst expectations of 89.7%.
A lower ratio indicates superior operational efficiency for insurers. Readings below the 90% threshold are typically viewed as evidence of strong cost management.
Looking ahead to Q2, Humana projects this metric will climb to slightly above 91%, suggesting emerging cost pressures on the horizon.
Management also observed that overall medical and pharmacy cost trends are tracking marginally better than anticipated, which Cantor analyst Sarah James identified as among the few encouraging elements in the quarterly report.
However, James raised red flags. “HUM has several signals that the back-half of the year could be difficult to manage,” she noted, describing the premarket selloff as “a warning sign.”
Humana indicated it will modify benefit structures as necessary to preserve stable profit margins. The federal government announced earlier this month that Medicare Advantage reimbursement rates would increase by an average of 2.48% for 2027.
Shares were last trading down approximately 2% in premarket activity after the initial 7.4% decline.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
